Aziyo Biologics introduced OsteGro® V, a viable cell bone matrix containing cancellous bone particles plus demineralized cortical bone particles and fibers.
OsteGro V joins Aziyo’s viable bone matrix platform that includes ViBone® and FiberCel® products. Aziyo entered into several non-exclusive private label distribution for OsteGro V for the orthopedic, spinal and dental markets.
“As we continue expand our portfolio of viable bone matrix products, we are pleased to be collaborating with multiple partners to deliver our newest generation of OsteGro that contains native bone cells,” said Ron Lloyd, President and Chief Executive Officer. “We are looking forward to leveraging our biologic expertise as well as our partners’ breadth of commercial expertise. These agreements illustrate our ongoing commitment to working with commercial partners to add innovative product options for orthopedic surgeons and their patients.”
Aziyo Biologics introduced OsteGro® V, a viable cell bone matrix containing cancellous bone particles plus demineralized cortical bone particles and fibers.
OsteGro V joins Aziyo’s viable bone matrix platform that includes ViBone® and FiberCel® products. Aziyo entered into several non-exclusive private label distribution for OsteGro V for the...
Aziyo Biologics introduced OsteGro® V, a viable cell bone matrix containing cancellous bone particles plus demineralized cortical bone particles and fibers.
OsteGro V joins Aziyo’s viable bone matrix platform that includes ViBone® and FiberCel® products. Aziyo entered into several non-exclusive private label distribution for OsteGro V for the orthopedic, spinal and dental markets.
“As we continue expand our portfolio of viable bone matrix products, we are pleased to be collaborating with multiple partners to deliver our newest generation of OsteGro that contains native bone cells,” said Ron Lloyd, President and Chief Executive Officer. “We are looking forward to leveraging our biologic expertise as well as our partners’ breadth of commercial expertise. These agreements illustrate our ongoing commitment to working with commercial partners to add innovative product options for orthopedic surgeons and their patients.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
